Evidence map›Paper›PMID 36995592›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2023

In Vitro Maturation of Human Pluripotent Stem Cell-Derived Myotubes.

Ricardo Mondragon-Gonzalez, Sridhar Selvaraj, Rita C R Perlingeiro

Abstract read
PubMed Publisher
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Ricardo Mondragon-GonzalezLillehei Heart Institute, Department of Medicine, University of Minnesota, Minneapolis, MN, USA.
Sridhar SelvarajLillehei Heart Institute, Department of Medicine, University of Minnesota, Minneapolis, MN, USA.
Rita C R PerlingeiroLillehei Heart Institute, Department of Medicine, University of Minnesota, Minneapolis, MN, USA. perli032@umn.edu.
Minneapolis Heart Institute Foundation · USUniversity of Minnesota · US

Funding

Targeting Dystroglycanopathies using Pluripotent-derived Myogenic ProgenitorsR01AR071439 · NIAMS · UNIVERSITY OF MINNESOTA · PI PERLINGEIRO, RITA C. R. · 2017 to 2021
$1.9M
NIAMS NIH HHS R01 AR071439
6 · The paper itself

Abstract

Pluripotent stem cells have a multitude of potential applications in the areas of disease modeling, drug screening, and cell-based therapies for genetic diseases, including muscular dystrophies. The advent of induced pluripotent stem cell technology allows for the facile derivation of disease-specific pluripotent stem cells for any given patient. Targeted in vitro differentiation of pluripotent stem cells into the muscle lineage is a key step to enable all these applications. Transgene-based differentiation using conditional expression of the transcription factor PAX7 leads to the efficient derivation of an expandable and homogeneous population of myogenic progenitors suitable for both in vitro and in vivo applications. Here, we describe an optimized protocol for the derivation and expansion of myogenic progenitors from pluripotent stem cells using conditional expression of PAX7. Importantly, we further describe an optimized procedure for the terminal differentiation of myogenic progenitors into more mature myotubes, which are better suited for in vitro disease modeling and drug screening studies.

Indexed as

Induced Pluripotent Stem CellsMuscular DystrophiesPluripotent Stem CellsCell DifferentiationHumansMuscle DevelopmentMuscle Fibers, SkeletalInduced pluripotent stem (iPS) cellsMyogenic differentiationMyotubesPAX7Small molecules

Identifiers

PMID36995592
OpenAlexW4361302073

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.